Denali Therapeutics Inc. (DNLI)
Summary
Will Recent Setbacks Impact Growth Prospects of DNLI Stock?
Denali Therapeutics gains FDA approval for Avlayah, but pipeline setbacks and partner exits raise fresh questions as key clinical programs continue.
DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?
Denali Therapeutics surges on Avlayah???s FDA approval, PRV sale and pipeline progress, but partnership changes and trial setbacks remain in focus.
Denali to Sell Priority Review Voucher for $195M Cash Boost
DNLI will gain $195M from selling its Rare Pediatric Disease PRV, adding non-dilutive capital to advance its clinical portfolio and growth plans.
Denali Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 195 | $2,728.2 | $4,490.85 | $1,762.65 | 64.61% |
| CD Carine Duboscq Groupama Asset Managment | 207,130 | $3.79M | $4.78M | $990,901.79 | 26.12% |
| BG Bart Gancher Intech Investment Management LLC | 38,931 | $566,150.91 | $897,359.55 | $331,208.64 | 58.5% |
 John H. Burbank III Passport Capital LLC | 3.73M | $88.09M | $86.02M | -$2.08M | -2.36% |
| YA Yinka Akinsola Blue Trust Inc. | 40 | $559.6 | $921.2 | $361.6 | 64.62% |
Denali Therapeutics Inc. (DNLI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Denali Therapeutics Inc. ever had a stock split?
Denali Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ryan J. Watts CEO | NASDAQ (NGS) Exchange | 24823R105 CUSIP |
| US Country | 443 Employees | - Last Dividend | - Last Split | 8 Dec 2017 IPO Date |
Overview
Denali Therapeutics Inc., a pioneering biopharmaceutical entity, dedicates its efforts to the development of a comprehensive portfolio of product candidates. These are specifically engineered to cross the blood-brain barrier, offering innovative therapies for neurodegenerative diseases and lysosomal storage diseases predominantly within the United States. Initially known as SPR Pharma Inc., Denali underwent a rebranding phase in March 2015, transitioning to its current identity. The foundation of Denali Therapeutics Inc. was laid in 2013, and its operational base is strategically located in South San Francisco, California. In its journey towards medical advancement, Denali Therapeutics maintains collaboration agreements with prominent industry leaders, including Biogen MA Inc., Biogen International GmbH, Genzyme Corporation, Takeda Pharmaceutical Company Limited, F-star entities, and Genentech, Inc., amongst others.
Products and Services
- DNL310 ETV (IDS enzyme replacement therapy) - Engineered for MPS II, this therapy illustrates Denali’s venture into lysosomal storage disorders, highlighting its commitment to addressing complex genetic conditions.
- TAK-594/DNL593 (for Frontotemporal Dementia-Granulin) and DNL126 program (for MPS IIIA) - Both under Phase 1/II, these programs exemplify focused efforts on degenerative and storage diseases, respectively, showcasing Denali’s versatility in tackling neurodegenerative disorders.
- DNL622 for MPS I (Hurler Syndrome) - Focuses on a lysosomal storage disorder, representing Denali's approach to genetic disease treatment through innovative therapeutic modalities.
- BIIB122/DNL151 LRRK2 inhibitor - A program aimed at Parkinson’s disease, it stands out for its brain-penetrant small molecule strategy, reflecting Denali’s groundbreaking attempts to target underlying disease mechanisms.
- SAR443820/DNL788 RIPK1 inhibitor - Geared towards CNS diseases, this inhibitor demonstrates Denali’s exploration into neuroinflammation as a therapeutic target.
- DNL343 eIF2B Activator - Targeting amyotrophic lateral sclerosis, it underscores Denali’s commitment to fatal neurodegenerative diseases by attempting to modify disease progression.
- SAR443122/DNL758 RIPK1 inhibitor - Aimed at peripheral inflammatory diseases, it showcases Denali’s ambition in extending its therapeutic reach beyond the central nervous system.
- Oligonucleotide Transport Vehicle platform & Antibody Transport Vehicle Amyloid beta program - These represent groundbreaking efforts to address diseases through genetic modulation and targeted therapy, underscoring Denali’s commitment to innovation in drug delivery and disease treatment mechanisms.
